Microarray Analysis Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Microarray Analysis Market Trends & Growth Drivers

Rising Use of Microarray in Non-Cancer Application Is Major Trend

• Microarray analysis has proved to be useful in antibiotic therapy, since bacterial genomic DNA outlasts the bacteria themselves in most situations.
• In such circumstances, DNA microarrays are commonly employed, since a diagnosis may be established using a tiny bit of DNA, rather than the greater number of bacteria required for a culture.
• In recent years, DNA-based microarrays have become the tool of choice for measuring gene expression.
• This is mostly due to the lower complexity and cost of usage, which allow this technology to become more accessible and standardized.

Growing Cancer Incidence Is Biggest Market Driver

• The biggest driver for the microarray analysis market is the increasing burden of cancer.
• Over the past 3–4 decades, the incidence of this disease has skyrocketed, with around 10 million dying of it each year.
• Cancer is caused by the mutation of certain genes, which causes cells to grow faster than they can naturally die.
• The mutation can be caused by an array of environmental factors or can be inherited.
• Hence, the understanding of the genes involved in the mutation is vital to enhancing prognosis and patient lives.
• Since its beginning in 2001, the Cancer Genome Anatomy Project has classified more than 40,000 genes responsible for cancer directly or indirectly.
• The complementary DNA (cDNA) microarray technology enables the identification of the expression of hundreds to thousands of genes at once, thus offering cost-effectiveness and speed in the laboratory.
• Microarray analysis helps study gene expression in a single sample or compare the expression of genes in healthy and diseased cells.
• Oligonucleotide and robotically spotted microarrays are the two most-common variants of this technology used for cancer diagnosis currently.
• One of their key applications in within oncology is head and neck cancer, specifically squamous cell carcinoma.
• The technology is being studied to identify molecular biomarkers of HNCs, which could enable sooner and more-precise diagnoses.
• Among the most common of HNCs is oropharyngeal cancer, caused by tobacco and alcohol consumption, human papilloma virus, and many other unexplained factors.
• As per research, HNC is the seven-most-prevalent cancer, with annual worldwide diagnoses and mortality of 660,000 and 325,000, respectively.
• Additionally, an epidemiological study conducted on the Middle Eastern population forecasts HNC incidence to rise substantially in people aged 50 and above, particularly in Qatar, Bahrain, and the U.A.E., till 2040.

Technical Challenges Could Restrict Market Growth

• Being a new technology for diagnosis, microarray analysis poses several technical challenges, which may hamper the growth of the market to some extent.
• Although it helps study thousands of genes in one go, it may need integration with supplemental technologies when studying genes with low expression levels or sample in which the RNA content is inadequate.
• Low-expression gene detection may also be hindered by non-specific probe binding or cross-hybridization.
• Additionally, when studying genes that express highly, they could be quantified inaccurately, leading to a muddling of the findings.
• Another challenge with this technology is the complexity of the datasets it creates, which necessitates high-tech data analysis tools.
• This might create an additional requirement for training laboratory personnel in the new software, which itself can be expensive, thus raising operational spending for users.
• Moreover, data privacy concerns persist, subjecting end users to stringent compliance regulations in developed countries.

Microarray Analysis Market Analysis

Offering Analysis

The consumables category holds the largest share, of 60%, in 2024, and it will witness the highest CAGR in the forecast period. This is owing to the surging count of research institutes and diagnostic laboratories utilizing microarray analysis. Moreover, the increasing research on mRNA and DNA methylation drives the consumption of consumables for carrying out microarray analyses. Contrary to instruments, consumables, such as reagents, chips, functionalized glass, slides, and functionalized cover slides, need to be procured frequently and in bulk. As the application of this technology expands into other clinical and research areas, the demand for the related consumables will only inflate.

The following offerings are covered in the report:

• Consumables (Largest and Fastest-Growing Category)
• Instruments
• Software & Services

Type Analysis

DNA microarrays hold the largest market share globally in 2024, and this category is expected to witness the highest CAGR, of 10%, during the forecast period. This is due to the fact that DNA microarrays are used in clinical diagnostic tests for a number of diseases. Additionally, they are used to determine which medicine might be best prescribed to a specific patient, because genes determine how the body handles the chemistry of drugs.

Moreover, DNA microarrays are majorly used to identify the mutations in the genetic structure of genes. For the analysis, short single-stranded DNAs of genetic disorders are produced, which are combined with the DNA of the patients. The DNA binds synthetically to the produced DNA, and the coherent material is used for the detection of the mutation type of cancer. Hence, the rising incidence of cancer is one of the major factors that contribute to the surge in the demand for DNA microarrays.

We have analyzed the below-mentioned types:

• DNA (Largest and Fastest-Growing Category)
• Protein
• Others

Application Analysis

The research category dominates the market with 55% share in 2024, attributed to the increasing private and public funding for proteomic and genomic research. The National Human Genome Research Institute funds a number of studies revolving around computational biology, the biology of diseases, structure of genomes, effectiveness of pharmaceuticals, and other topics. Among its greatest achievements is the Human Genome Project, carried out from 1997 to 2023 with a spending of around USD 3 billion. Similarly, the All of Us research program of the National Institutes of Health is focused on precision medicine.

The diagnostics category is witnessing the fastest growth in the market on account of the rising incidence of chronic diseases, especially those with a genetic component. The most-common genetic diseases include cystic fibrosis, sickle cell disease, cancer, hypertension, diabetes, and neurodegenerative diseases (Huntington’s, Parkinsons’ and Alzheimer’s). As per the International Diabetes Federation, the number of people with diabetes around the world is expected to rise to 783 million by 2040 from 536 million in 2021.

These applications have been analyzed:

• Research (Largest Category)
• Drug Discovery
• Diagnostics (Fastest-Growing Category)
• Others

End User Analysis

Research & academic institutes hold the largest share in 2024, and the value of the sale of the associated products to these users is expected to reach over USD 6 billion by 2032. The count of human genome study projects has increased in the past few years. Majorly, microarrays are used for the discovery of cancer drugs. Hence, the increasing R&D investments in the healthcare sector are expected to fuel the market growth.

Pharmaceutical & biotechnology companies are expected to witness the fastest market advance, as several research programs are conducted by them for the development of drugs. Additionally, major biotechnology companies are engaging in mergers and acquisitions to enhance their product portfolio for drug discovery applications. Moreover, because of its ability to identify the nature and functioning of biomolecules, microarray analysis, particularly protein microarrays, are being increasingly adopted in personalized medicine. In this regard, the growing cancer drug R&D spending will drive the market in this category.

The report offers analysis of these end users:

• Research & Academic Institutes (Largest Category)
• Pharmaceutical & Biotechnology Companies (Fastest-Growing Category)
• Diagnostic Laboratories
• Others

Regional Analysis

• Globally, North America accounts for the largest market share, of 40%, in 2024. It is expected to witness significant growth during the forecast period, owing to the fact that governments in the U.S. and Canada are continuously increasing their funding for cancer research.
• The American Cancer Society has estimated 1.9 million new cases and 609,360 deaths from cancer in the U.S. in 2022.
• Obesity and aging are cited as the major causes of cancer in the country. More than 2 in 5 people in the country are obese, as per the Centers for Disease Control and Prevention (CDC).
• This is itself attributed to the excessive consumption of alcohol and fatty foods, including fast food and red meats.
• Moreover, the two regional countries are home to all major biotechnology companies, which enables easy access to the instruments and consumables needed for microarray analyses.
• In the same way, the presence of key IT companies leads to the wide availability of accompanying software for the instruments.
• APAC will witness the highest CAGR, of 9.5%, over the forecast period, ascribed to the increasing prevalence of chronic diseases and the rising focus on precision medicine.
• As per the Global Cancer Observatory of the World Health Organization, 4,824,703 people were diagnosed with cancer, and 2,574,176 died of it in China in 2022.
• The numbers for Japan stood at 1,005,157 new cases and 426,278 deaths.
• With the increasing burden of this and other diseases with a genetic component, governments are augmenting their spending on genomic research.
• The Genome India project, for instance, had sequenced 10,000 native Indian genomes by March 2024.
• Moreover, in collaborations with international agencies, researchers revealed an aberration in a cardiac myosin binding protein C, MYBPC3, as being related to heart failure.
• With genomic research yielding more such findings, the outcomes for patients with rare diseases would improve, and microarray analysis could fine even more applications.

The following is the regional analysis of the market:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • U.K. (Fastest-Growing Country Market)
  • Germany (Largest Country Market)
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Fastest-Growing Country Market)
  • South Africa (Largest Country Market)
  • Rest of MEA

Microarray Analysis Market Share

The microarray analysis market is fragmented as only major biotechnology firms with ample R&D and financial capabilities can develop the tools and consumables necessary for such studies. Additionally, larger companies have been quick to acquire biotechnology startups with a high potential, for business growth and sustained dominance. Moreover, developed countries and many developing ones have stringent regulations for diagnostic tools, which only established companies can comply with.

Microarray Analysis Market Company News

• In September 2024, Agilent Technologies Inc. launched its Biopharma CDx Services Lab in California post regulatory approvals. The lab will offer solutions for all phases of the drug development process with companion diagnostics, as well as provide innovative technologies for assessing biomarkers with new personalized drugs in clinical trials, in addition to offering assays that provide comprehensive robust data.
• In August 2024, Illumina Inc. announced the FDA approval for its TruSight Oncology (TSO) biomarker test kit with two companion diagnostics. The test evaluates up to 500 genes to classify a solid tumor.
• In July 2024, Danaher Corporation announced a research collaboration with Lundberg and the Department of Bioengineering at Stanford University to detect spatial, metabolic, and proteomic changes in the tumor microenvironment and predict the effect of potential therapies.
• In June 2024, Merck KGaA completed the EUR 180-million expansion of its Schnelldorf Distribution Center. Expanded by 25,000 sq m, the facility will enable the company to better supply a wide variety of products to research facilities and laboratories.